T1	PROC 49 64	estudio clínico
#1	AnnotatorNotes T1	C0008972; Clinical Research; Research Activity | C0008976; Clinical Trials; Research Activity
T2	PROC 70 101	evaluar la seguridad y eficacia
T3	PROC 120 131	tratamiento
#2	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	DISO 163 193	distrofia muscular de Duchenne
#3	AnnotatorNotes T4	C0013264; Muscular Dystrophy, Duchenne; Disease or Syndrome
T5	DISO 195 198	DMD
#4	AnnotatorNotes T5	C0013264; Muscular Dystrophy, Duchenne; Disease or Syndrome
T6	PROC 258 299	Estudio de extensión abierto, en fase III
T7	PROC 305 339	evaluar la seguridad y la eficacia
#5	AnnotatorNotes T7	C0511730; Identify product efficacy and safety issues; Health Care Activity
T8	CHEM 357 366	idebenona
#6	AnnotatorNotes T8	C0123163; idebenone; Organic Chemical · Pharmacologic Substance
T9	DISO 384 414	distrofia muscular de Duchenne
#7	AnnotatorNotes T9	C0013264; Muscular Dystrophy, Duchenne; Disease or Syndrome
T10	DISO 416 419	DMD
#8	AnnotatorNotes T10	C0013264; Muscular Dystrophy, Duchenne; Disease or Syndrome
T11	DISO 487 490	DMD
#9	AnnotatorNotes T11	C0013264; Muscular Dystrophy, Duchenne; Disease or Syndrome
T12	DISO 498 517	enfermedad genética
#10	AnnotatorNotes T12	C0019247; Hereditary Diseases; Disease or Syndrome
T13	DISO 536 554	debilidad muscular
#11	AnnotatorNotes T13	C0151786; Muscle Weakness; Sign or Symptom
T14	DISO 557 572	pérdida de peso
#12	AnnotatorNotes T14	C1262477; Weight decreased; Finding
T15	DISO 614 626	discapacidad
#13	AnnotatorNotes T15	C0231170; Disability; Finding
T16	DISO 660 690	Distrofia muscular de Duchenne
#14	AnnotatorNotes T16	C0013264; Muscular Dystrophy, Duchenne; Disease or Syndrome
T17	PROC 799 823	consentimiento informado
#15	AnnotatorNotes T17	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T18	CHEM 1371 1403	fármaco en fase de investigación
#16	AnnotatorNotes T18	C0013230; Investigational New Drugs; Pharmacologic Substance
T19	CHEM 1418 1428	medicación
#17	AnnotatorNotes T19	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T20	CHEM 136 145	idebenona
#18	AnnotatorNotes T20	C0123163; idebenone; Organic Chemical · Pharmacologic Substance
T21	ANAT 173 181	muscular
#19	AnnotatorNotes T21	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T22	ANAT 394 402	muscular
#20	AnnotatorNotes T22	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T23	ANAT 546 554	muscular
#21	AnnotatorNotes T23	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T24	ANAT 670 678	muscular
#22	AnnotatorNotes T24	C0026845; Muscle Tissue; Tissue | C4083049; Muscle (organ); Body Part, Organ, or Organ Component
T25	Date 13 17	2017
T26	Date 102 115	a largo plazo
T27	LIVB 149 158	pacientes
#23	AnnotatorNotes T27	C0030705; Patients; Patient or Disabled Group
T28	Date 340 353	a largo plazo
T29	LIVB 370 379	pacientes
#24	AnnotatorNotes T29	C0030705; Patients; Patient or Disabled Group
T30	LIVB 890 899	pacientes
#25	AnnotatorNotes T30	C0030705; Patients; Patient or Disabled Group
T32	LIVB 1184 1196	investigador
#26	AnnotatorNotes T32	C0035173; Research Personnel; Professional or Occupational Group
T35	LIVB 1230 1238	paciente
#27	AnnotatorNotes T35	C0030705; Patients; Patient or Disabled Group
T36	LIVB 1322 1330	paciente
#28	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	Neg_cue 1408 1410	no
T38	GENE 509 517	genética
#29	AnnotatorNotes T38	C0017337; Genes; Gene or Genome
T39	Date 772 781	semana 78
T31	PROC 996 1003	visitas
#30	AnnotatorNotes T31	C1512346; Patient Visit; Health Care Activity
T33	Neg_cue 968 970	no
T34	Quantifier_or_Qualifier 770 771	8
T40	PROC 763 769	visita
#31	AnnotatorNotes T40	C1512346; Patient Visit; Health Care Activity
A1	Assertion T19 Negated
A2	Assertion T31 Negated
#32	AnnotatorNotes T2	C0511730; Identify product efficacy and safety issues; Health Care Activity
T41	Quantifier_or_Qualifier 986 991	todas
A3	Assertion T41 Negated
T42	Spec_cue 1198 1204	puedan
T43	Observation 1205 1226	poner en grave riesgo
A4	Assertion T43 Speculated
R1	Speculation Arg1:T42 Arg2:T43	
T44	CONC 1265 1275	interferir
A5	Assertion T44 Speculated
#33	AnnotatorNotes T44	C0521102; Interferes with; Functional Concept
R2	Speculation Arg1:T42 Arg2:T44	
T45	Observation 1304 1330	participación del paciente
#34	AnnotatorNotes T45	C1278516; Patient participation status; Finding
R3	Overlap Arg1:T2 Arg2:T26	
R4	Used_for Arg1:T20 Arg2:T3	
R5	Experiences Arg1:T27 Arg2:T3	
R6	Experiences Arg1:T27 Arg2:T4	
R7	Experiences Arg1:T27 Arg2:T5	
R8	Location_of Arg1:T21 Arg2:T4	
R9	Location_of Arg1:T21 Arg2:T5	
T46	Observation 204 226	completaron el estudio
#35	AnnotatorNotes T46	C2732579; Completion of clinical trial; Finding
R11	Before Arg1:T46 Arg2:T2	
R12	Before Arg1:T46 Arg2:T1	
T47	Observation 431 452	completado el estudio
#36	AnnotatorNotes T47	C2732579; Completion of clinical trial; Finding
R13	Experiences Arg1:T29 Arg2:T8	
R14	Experiences Arg1:T29 Arg2:T9	
R15	Experiences Arg1:T29 Arg2:T10	
R17	Before Arg1:T47 Arg2:T6	
R18	Before Arg1:T47 Arg2:T7	
R19	Overlap Arg1:T7 Arg2:T28	
R20	Location_of Arg1:T22 Arg2:T9	
R21	Location_of Arg1:T22 Arg2:T10	
R23	Causes Arg1:T11 Arg2:T13	
R24	Causes Arg1:T11 Arg2:T14	
R25	Location_of Arg1:T23 Arg2:T13	
T48	Observation 573 595	rápidamente progresiva
#37	AnnotatorNotes T48	C1838681; Rapidly progressive; Finding
R26	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T48	
R27	Causes Arg1:T11 Arg2:T15	
R28	Before Arg1:T14 Arg2:T15	
R29	Before Arg1:T13 Arg2:T15	
R30	Location_of Arg1:T24 Arg2:T16	
T49	Quantifier_or_Qualifier 627 633	severa
#38	AnnotatorNotes T49	C1547227; Severe - Severity of Illness Code; Intellectual Product
R31	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T49	
R32	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T34	
T50	Observation 727 748	completado el estudio
#39	AnnotatorNotes T50	C2732579; Completion of clinical trial; Finding
R33	Overlap Arg1:T50 Arg2:T40	
R34	Overlap Arg1:T50 Arg2:T39	
R35	Negation Arg1:T33 Arg2:T31	
R36	Negation Arg1:T33 Arg2:T41	
R37	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T41	
R39	Negation Arg1:T37 Arg2:T19	
T51	Quantifier_or_Qualifier 1429 1440	del estudio
A6	Assertion T51 Negated
R40	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T51	
R41	Negation Arg1:T37 Arg2:T51	
T52	Observation 1028 1067	Problemas relacionados con la seguridad
#40	AnnotatorNotes T52	C4716889; Safety issues related to medication; Finding
T53	Observation 1028 1054;1069 1085	Problemas relacionados con la tolerabilidad
T54	PROC 1145 1152	estudio
A7	Status T54 History_of
#41	AnnotatorNotes T54	C0008976; Clinical Trials; Research Activity
R42	Overlap Arg1:T53 Arg2:T54	
R43	Overlap Arg1:T52 Arg2:T54	
R44	Before Arg1:T53 Arg2:T43	
R45	Before Arg1:T52 Arg2:T43	
R46	Experiences Arg1:T35 Arg2:T53	
R47	Experiences Arg1:T35 Arg2:T52	
R50	Experiences Arg1:T35 Arg2:T45	
R51	Experiences Arg1:T36 Arg2:T53	
R52	Experiences Arg1:T36 Arg2:T52	
#42	AnnotatorNotes T41	C0444868; All; Quantitative Concept
#43	AnnotatorNotes T26	C0443252; Long-term; Temporal Concept
#44	AnnotatorNotes T28	C0443252; Long-term; Temporal Concept
A8	Experiencer T29 Patient
A9	Experiencer T27 Patient
A10	Experiencer T30 Patient
A11	Experiencer T32 Other
A12	Experiencer T35 Patient
A13	Experiencer T36 Patient
